Cellares’ Post

Check out our this new article that features Cellares and talks about how our technology addresses an unmet need!

In the Newsweek article, "The Many Faces of Oncology”, our Co-Founder & CEO, Fabian Gerlinghaus, highlights a significant issue: 'About 20 percent of patients are dying on the waitlist even though they are eligible for approved cell therapies because the industry is unable to meet patient demand.' This is a medical emergency. Learn more about how Cellares' Cell Shuttle platform integrates and automates the entire cell therapy manufacturing process, reducing labor and space requirements by 90% and processing 16 cell therapies simultaneously. This industry 4.0 approach aims to meet global patient demand for these life-saving cell therapies. Read now: https://lnkd.in/gsYX84RB For more Cellares coverage, check out the 🔗 link in the comments!

This article, authored by Dr. Bruce L. Levine and a team of scientists, delves into the FDA's investigation on T cell malignancies post-CAR-T cell therapy, emphasizing the need for long-term monitoring and investigating potential causal links. The article highlights the importance of investigating potential causal links between CAR-T therapy and T cell malignancy, providing insights into reported cases and comparing risks with other treatments. The authors recommend continued use of CAR-T therapies, pending FDA results, and stress the importance of adherence to safety studies and prompt reporting of subsequent malignancies. https://lnkd.in/euHw852a

For cell therapies, the path to the clinic is marked by critical scientific and regulatory milestones that require careful planning, expertise, and collaboration. On March 7, join Premier Research and BioCentriq as we discuss the intricacies of early cell therapy development that shape the path toward clinical trials. Mark you calendars: https://bit.ly/3UlHBk5

The article underscores the significance of examining possible connections between CAR-T therapy and T cell malignancy. It offers insights into documented cases, compares risks with alternative treatments, and suggests the ongoing use of CAR-T therapies, awaiting FDA findings. Emphasis is placed on adhering to safety studies and promptly reporting any subsequent malignancies. #MedicalInnovations #CancerResearch #TreatmentSafety #FDAUpdates #MalignancyInvestigation #TherapyRisks #HealthcareRecommendations #ScientificInsights #PatientSafetyFocus

targeting both of CD19 and CD22 is one of the options for Antigen 19 loss besides other tumor related resistance mechanisms

Early-phase cell therapy clinical trials come with distinct bioanalytical challenges and evolving regulatory considerations. Next week, we’ll be releasing an on-demand webinar titled ‘Persistence is key: Bioanalytical Strategies for Cell Therapy Clinical Trials,’ where we navigate the challenges and complexities of designing early-phase studies for cell therapies. Presented by Caroline Beltran PhD, this webinar will cover key topics such as potency, immunogenicity, cell expansion, pharmacodynamics and long-term persistence. Register to be notified and gain instant access when the webinar becomes available next week. https://lnkd.in/eaeMrs8E #Synexa #webinar #celltherapy #clinicaltrial

Our latest article highlights a process that reduces the time to manufacture autologous CAR-T cells from 7-14 days to just 24 hours! This next-gen, automated, closed, lentivirus-based method not only improves efficiency but also brings manufacturing closer to patients, enhancing accessibility and expanding the reach of life-saving treatments. 🌟 Discover how decentralizing cell therapy manufacturing can overcome barriers and improve patient outcomes. Read the full story and explore the future of point-of-care cell therapies: https://lnkd.in/gy7GC8a4

Congratulations Adaptimmune on securing the first FDA approval for TCR-T in solid tumors! 🎉 At the forefront of what can be accomplished with cell therapy and changing the treatment landscape for patients with synovial sarcoma! Another Immudex GMP Dextramer customer making major clinical impacts in cell therapy! Check out Adaptimmune's paper from last year characterizing afami-cel using Dextramer reagents (Hong et. al., Nature Medicine 2023).

Significant progress has been achieved in the realm of therapeutic interventions for multiple myeloma (MM), leading to transformative shifts in its clinical management. This article provides an overview of CAR-T cell therapy in Multiple Myeloma (MM), the utilization of B-cell maturation antigen (BCMA) as the target antigen, and an overview of other target moieties. https://lnkd.in/gsEejDfc